Habib Hamidi

Jan 14, 2025 | sciencedirect.com | Habib Hamidi |Romain Banchereau |David Hsiehchen |Hao Yue Zhu

Chimeric antigen receptor (CAR) T cell therapy targeting CD19 has transformed the treatment of refractory B cell non-Hodgkin’s lymphomas (B-NHL), including diffuse large B cell lymphoma (DLBCL) and multiply relapsed follicular lymphoma (FL).1,2,3,4,5 However, only 30%–40% of DLBCL and FL patients maintain durable complete remission after five years.6,7,8,9,10,11,12 The reasons behind such variable outcomes remain enigmatic, and cellular immunotherapies are currently administered without...

Nov 21, 2024 | cell.com | Habib Hamidi |Yasin Senbabaoglu |Niha Beig |Juliette Roels |Cyrus Manuel |Xiangnan Guan | +26 more

Keywordsurothelial carcinomatranscriptomicsmolecular heterogeneityPD-L1 blockadepatient stratificationdigital pathologyGet full text accessLog in, subscribe or purchase for full access. References1. Ishida, Y. ∙ Agata, Y. ∙ Shibahara, K. ... Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell deathEMBO J. 1992; 11:3887-38952. Tang, J. ∙ Yu, J.X. ∙ Hubbard-Lucey, V.M. ...